Add to Calendar    

The generic drug market makes up over 40% of the global drug market. Currently, the global generic drug market has a value of 80 billion US dollars and is growing at a rate of 8% while the generic drug industry of China is growing at a tremendous rate of 25%. As the 12th Five-Year Plan stipulates that the quality of generic drugs should be enhanced comprehensively, China’s generic drug market will change its strategy from “mere imitating” to “innovation”. Undoubtedly, the huge domestic market of generic drugs will be subject to the market criterion of “survival of the fittest”. In recent years, new drugs are getting fewer on overseas market and the world’s bulk drug industry is gradually shifting itself towards developing countries. The next few years will see the peak period of patent expiry for international drugs. China and many other developing countries will become major transfer destinations of the generic drug industry for further growth. In such a situation, generic drugs promise to become a “footboard” for China’s pharmaceutical industry. Pharmaceutical enterprises may combine imitation with manufacture and have much to do in process innovation on China’s generic drug market, which is characterized by “domestication of international competition and internationalization of domestic competition”.

Delving into road-map of generics regulatory updates, process quality & R&D channels;
Concern-solving & insights hearing from 25+ domestic and overseas speakers under CPhl resources;
Getting on-spot answers to your critical business by 2-day’s 15+ industry issue interactive sharing and peer networking;
Covering 3 hot topics: Seminar of international & domestic regulatory concerning generic drugs; Analysis of process quality & innovation of generic drugs; New ideas of cooperation & R&D for generic drugs;
Networking with 120+ decision makers from 30+ China’s pharmaceutical companies and 20+ MNCs in the category of drug manufacturing;
Brainstorming domestic and overseas generics qualifying standards so as to seek out market growing performances and the assessment approval of generics consistency + 2 leaders’ think tank about generic pharma operational methodologies to find out the new opportunities in the generics value chain

Decision makers/R&D/QA，QC/Product Development/Regulatory Affairs/BD/Marketing
From:  Generics Manufacturers/Innovator Pharma Manufacturers/CRO,CMO/Ingredient & Material Suppliers/Equipment Suppiers/Government Associations/Analytical Laboratories

  Past attendees’comments:

 2-day conference made me in deeper understanding of China generics technology dynamics and networking with many industrial professionals and peers。
                                                                                                                                           -- Zhao Xiaowei, Project Manager, FERGUSON
Getting to acquire generics impurity spectrum technical qualifications, the assessment of generics consistency, USP Pharmacopoeia knowledge
                                                                                                                --Zhang Suoqing, R&D Manager, North China Pharmaceutical
Getting to know the latest standards for domestic pharmaceutical research progressing
                                                      --Zhu Dequan, Assistant President/BD Director,SICHUAN HUIYU PHARMACEUTICAL CO., LTD

  Past Participants Analysis: